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Abstract
Here I review the current status of geographical occurrence and public health significance of echinococcosis (Echinococcus spp. infections)
and cysticercosis (Taenia solium infection) with special emphasis on the remarkable technologic progress achieved in recent decades that has led
to greater understanding of the biology and epidemiology of these cestode infections. The greatest remaining challenges are to apply this
knowledge and technology to improved medical management and prevention of these infections.
D 2005 Published by Elsevier Ireland Ltd.
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1. Introduction
Thank you for this opportunity to share my experiences and
observations for the future in research, treatment and control of
echinococcosis and cysticercosis/taeniasis. My experience is
shaped by my activities directed toward these cestode parasites
in the field and in the laboratory. I first encountered Taenia solium
taeniasis/cysticercosis as a Fellow in Medical Parasitology at the
National University in Mexico and at that time only the most
serious of cases of neurocysticercosis were correctly diagnosed,
often at autopsy. I first encountered echinococcosis in California
when, upon visiting a local slaughterhouse to collect cysticerci of
Taenia hydatigena, we noted hydatid cysts in the viscera of sheep.
This led to the work that formed my PhD thesis at the University
of California Davis. Upon completion of graduate study I began a
job as Epidemiologist at the Pan American Health Organization’s
Zoonoses Research Center (CEPANZO) in Buenos Aires,
Argentina. A major emphasis of our program was working with
scientists at Latin American government institutions in carrying
out research and implementing control programs against echino-
coccosis. In 1974 I had the opportunity to join the U.S. Public
Health Service at the Centers for Disease Control and Prevention
in Atlanta. In these positions I have had the opportunity to work
with scientists from many countries in research and control of
parasitic zoonoses with special emphasis on echinococcosis and
cysticercosis. It gives me pleasure to reflect upon these
experiences and to marvel at just how far we have progressed in
the understanding of these zoonotic infections and in development
of technology that is effectively applied to diagnosis, treatment
and control of these infections.
2. Echinococcosis
Until recently, the genus Echinococcus had contained 4
generally accepted species: Echinococcus granulosus (Batsch,
1786), Echinococcus multilocularis (Leuckart, 1863), Echino-
coccus oligarthrus (Diesing, 1863), and Echinococcus vogeli
(Rausch and Bernstein, 1972) are morphologically distinct in
both adult and larval stages [1,2].
One of these species, E. granulosus, is made up of a number
of biologically and genetically distinct entities, whose taxo-
nomic positions are in states of flux. These variants are
separated ecologically, although not necessarily geographically,
by the nature of their respective unique host assemblages. They
have been referred to as strains or subspecies [2], however,
recent proposals have elevated a number of them to separate
species status. Current data, based on genome patterns,
generally support previous characterizations based on morpho-
logic and biologic criteria: at least 10 genetically distinct
populations exist within the complex until recently denoted E.
granulosus [2] (Table 1). Probes characterizing the mitochon-
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drial and genomic DNA of the variant populations provide
reliable genetic markers to distinguish them [1–3]. It is likely
that the speciation question will be debated for some time and,
until it is further clarified, it is important to recognize that
important biologic differences exist between populations
presently identified in many texts as E. granulosus, the
causative agent of cystic echinococcosis, and that these may
account for local differences in patterns of transmission and
clinical and public health significance of the disease.
2.1. Cystic echinococcosis (CE)
In many countries of these endemic regions, national
diagnostic incidence rates of CE range from 5 to 20 per
100,000 population [4]. ‘‘National’’ rates are misleading,
however, because most urban populations are at low risk; in
rural endemic areas diagnostic incidence is manyfold higher.
Furthermore, rates based on clinically diagnosed cases under-
estimate the burden of infection; surveys of populations in
endemic populations using ultrasound imaging diagnostic
techniques often measure CE prevalences of 2% to 6%,
manyfold higher than evident from clinically diagnosed cases
[5–7].
Socioeconomic and cultural characteristics are among the
best-defined risk factors for human infection with CE
throughout its broad global range: uncontrolled dogs living
closely with people, uncontrolled slaughter of livestock, and
insanitary living conditions [4]. Whether it be among Arabs in
Tunisia, Quechua Indians in Peru, Turkana tribesmen in Kenya,
or Tibetans in China these common factors are readily
discernible. Consistently highest prevalence is found among
populations involved with sheep raising, thus emphasizing the
predominant public health importance of the sheep genotype E.
granulosus (G1). In these regions the social and economic
impacts of the infection can be highly significant [4,8].
Although mortality rates associated with hydatid disease
may appear low in comparison with those for some other
infectious diseases, the morbidity associated with each case is
considerable. Patients with hydatid disease often require
multiple surgical interventions. Extensive secondary hydatid
Table 1
Characteristics of hosts and known geographic distribution of recognized and proposed species and strains in the genus Echinococcus
Species strain/isolate
(genotype)
Known intermediate hosts Infective to
humans?
Known definitive hosts Probable geographical distribution Proposed taxonomic
designation
Echinococcus granulosus
Sheep strain (G1) Sheep, cattle, pigs, Camels,
goats, macropods
Yes Dog, fox, dingo, jackal
and hyena
Australian mainland, Europe,
USA, New Zealand, Africa, China,
Middle East, South America and
Russian Federation
E. granulosus
Tasmanian sheep strain (G2) Sheep, cattle? Yes Dog, fox Tasmania, Argentina E. granulosus
Buffalo strain (G3) Buffalo, cattle? ? Dog, fox? Asia E. granulosus
Horse strain (G4) Horses and other equines No Dog Europe, Middle East, South Africa Echinococcus equinus
Cattle strain (G5) Cattle Yes Dog Europe, South Africa, India, Nepal,
Russian Federation, South America?
Echinoccus ortleppi
Camel strain (G6) Camels, goats, cattle? Yes Dog Middle East, Africa, China, Argentina E. granulosus?
Pig strain (G7) Pigs Yes Dog Europe, Russian Federation,
South America
E. intermedius
Cervid strain (G8) Moose, caribou, reindeer Yes Wolf, coyote, dog North America, Eurasia E. granulosus
Fennoscandinavian
cervid strain (G10)
Reindeer, moose? ? Wolf, dog Eurasia E. granulosus?
Lion strain Zebra, wildebeest warthog,
bushpig buffalo,
various antelope, giraffe?
Hippopotamus?
? Lion Africa E. granulosus?
Echinococcus multilocularis
European isolate Rodents, domestic and
wild pig, dog, monkey
Yes Fox, dog, cat,
wolf raccoon–dog
Europe, China? E. multilocularis
Alaskan isolate Rodents Yes Fox, dog, cat Alaska E. multilocularis
North American isolate Rodents Yes Fox, dog, cat, coyote North America E. multilocularis
Hokkaido isolate Rodents, pig monkey,
horse
Yes Fox, dog, cat raccoon–dog Japan E. multilocularis
Echinococcus vogeli
(None reported) Rodents Yes Bush dog Central and South America E. vogeli
Echinococcus oligarthrus
(None reported) Rodents Yes Wild felids Central and South America E. oligarthrus
Echinococcus shiquicus
(None reported) Rodents, lagomorphs? Tibetan fox Tibetan Plateau (China) E. shiquicus
Modified from Thompson and McManus [1].
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disease often becomes inoperable, and involvement of the
bones usually requires amputation. Economic losses to affected
families include surgical and hospital expenses as well as loss
of income. Published data on the ‘‘burden’’ of echinococcosis
from many countries extensively document the severe impact
of these infections in terms of their impact on human health and
productivity as well as the monetary losses incurred as a result
of infection in livestock hosts [8].
Recent investigations in China have demonstrated that, in
addition to direct medical costs, the long-term quality of life in
patients treated for CE and AE was permanently affected
indicating that morbidity is more subtle and considerably
greater than previously appreciated. Budke and others [9]
determined that individuals who were previously unaware they
had the disease, but diagnosed with CE or AE in a random
cross-sectional study using abdominal ultrasound, experienced
a significant decrease in the quality of life associated with
receiving a positive diagnosis of CE or AE. Their investigation
determined that the DALYs (disability adjusted life years) lost
due to these infections in terms of medical treatment costs, lost
income, and physical and social suffering, was substantial.
Such decreases in the quality of life presumably have
significant economic effects including impairment in the work
place and thus having less highly paid work than would
otherwise have been the case, having greater levels of
absenteeism from work, or possibly requiring greater levels
of long term nursing care.
Imaging technology developed in recent years has revolu-
tionized detection of hydatid cysts and other space-occupying
lesions in all parts of the body. Computed tomography (CT),
magnetic resonance imaging (MRI), and ultrasound imaging
are all useful for detecting and for defining the extent and
condition of avascular fluid-filled cyst(s) in most organs [10].
These noninvasive imaging techniques have proved invaluable
for diagnosis and preoperative evaluation by staging the
condition of the lesion (intact; unilocular; ruptured; complicat-
ed with daughter cysts; and calcified), the extent of the lesion
in reference to other organs and vital structures, and identifying
the presence of additional, occult lesions. Ultrasonography,
because of its relatively low cost and portability, has been used
widely for screening, clinical diagnosis, and monitoring of
treatment of liver and intra-abdominal cysts [11]. The WHO
Informal Working Group on Echinococcosis (WHO-IWGE)
proposed a standard ultrasound classification of hydatid cysts
based on their ultrasound appearance consistent with the
natural history of the disease and response to treatment which
is useful for defining the extent and condition of the cyst(s)
[12]. The standardized classification scheme is intended to
promote uniform standards of diagnosis and treatment and may
be applied to clinical management of patients as well as to field
diagnostic surveys.
Serologic tests are useful for confirming presumptive
imaging diagnoses; however, the limitations of serodiagnosis
in cystic echinococcosis must be understood to correctly
interpret the findings. Specific confirmation of reactivity can
be obtained by demonstrating echinococcal antigens by
immunodiffusion (arc 5) procedures or immunoblot assays
(8-, 16-, 21-kDa bands) [13,14]. These latter serodiagnostic
markers are the most E. granulosus-specific criteria described,
but even they may be detected in serum of patients with other
forms of echinococcosis and 5% to 10% of patients with T.
solium cysticercosis [15].
Until recent decades, surgery was the only option for
treatment of echinococcal cysts, however, chemotherapy with
benzimidazole compounds and, more recently, cyst puncture,
and percutaneous aspiration, injection of chemicals, and
reaspiration (PAIR) are increasingly seen to supplement or
even replace surgery as the preferred treatment. The benefits
and limitations of current treatment options have been critically
reviewed by consultants for the World Health Organization
(WHO) Informal Working Group on Echinococcosis [16].
The development and use of ultrasound imaging technology
for clinical diagnosis and population screening has led to
significant improvements in clinical management of abdominal
forms of echinococcosis and has provided new information on
the natural history of the disease; it is now clear that many, if
not the majority of cases of CE, have a benign prognosis. This
knowledge has led to new, unanswered questions about the
necessity for, criteria for, and selection of appropriate
treatments. Development of definitive guidelines is still
hampered by the lack of a) complete knowledge of the natural
history of the disease, b) properly powered clinical trials, and c)
adequate long term follow-up. Coordination of effort in long-
term multicenter trials will be crucial to significantly improve
knowledge and technology of treatment.
E. granulosus has been viewed as highly vulnerable to the
implementation of preventive measures, at least in theory.
When only synanthropic hosts under human control are
involved, the cestode cycle can be interrupted if dogs are
prevented from consuming infected viscera from sheep and
other domestic ungulates. Indeed, there are now a number of
successful examples of echinococcosis control, achieved on a
national or regional scale, that confirm that E. granulosus is
relatively unstable in synanthropic hosts and responds readily
to comprehensive and consistently applied measures of
intervention [4,17].
Progress in developing effective vaccination against infec-
tion with oncospheres and immunotherapy of the metacestode
have been reviewed by Lightowlers and others [18]; vaccina-
tion may provide an additional tool for control and prevention
of this infection.
2.2. Alveolar echinococcosis (AE)
Being largely confined to life cycles involving foxes and
arvicolid rodents, in ecosystems generally separate from
humans, exposure of humans to E. multilocularis is relatively
less common than exposure of humans to E. granulosus, the
cause of cystic echinococcosis. Fox trappers and other persons
who work with foxes or their fur would appear to be relatively
frequently exposed to eggs of E. multilocularis, but these
occupations have not been associated with higher rates of
infection [19,20]. There is ecological overlap to humans
because domestic dogs or cats may become infected when
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they eat infected wild rodents and infected pets are an
important source of infection for humans [21]. Hyperendemic
foci have been described in some Native American villages of
the North American tundra (now largely disappeared) and in
China [4–6,22] where local dogs regularly feed on infected
commensal rodent and lagomorph intermediate hosts. Under
these circumstances, indirect or direct contamination from
feces of infected dogs appears to be the most important source
of infection and human infection prevalence may reach 2–6%
[5,6].
E. multilocularis has an extensive geographic range in the
Northern Hemisphere, widespread and increasing in Europe,
most of northern Eurasia, from Bulgaria and Turkey through
most of Russia, and the newly independent nations of the
former U.S.S.R., extending eastward to several of the Japanese
islands [4]. Recent surveys in Central Europe have extended
the known distribution of E multilocularis from four countries
at the end of the 1980s to at least 11 countries in 1999 [23]. The
incidence of diagnosed disease in humans remains low,
between 0.02 and 1.4 per 100,000 for entire countries or larger
regions of endemicity. Between 1982 and 2000, 559 cases of
alveolar echinococcosis in humans were reported voluntarily
from nine European countries to the European Echinococcosis
Registry [24]. The cestode appears to have spread eastwards in
Europe in association with increased populations of foxes and
this may herald the emergence of AE in humans in central
Eastern Europe. Surveys of foxes in Germany and France
carried out in the mid-1990s compared recent data with that
collected in the 1970s and 1980s, and documented higher fox
densities as well as increased prevalences of E. multilocularis
infection [25]. New human cases have been reported during the
last 10 years in several European countries previously
considered non-endemic: i.e. Belgium, Netherlands, Luxem-
bourg, Czech Republic, Slovak Republic, Poland, Italy,
Slovenia, Hungary, Bulgaria and Romania [24]. Increasing
fox populations, increasing encroachment of foxes into urban
areas and spillover of E. multilocularis infection from wild
carnivores to domestic dogs and cats might presage increased
public health risks of AE [26].
The known distribution and prevalence of infection in foxes
and coyotes has increased in the United States and now extends
from Montana in the West to western Ohio in the East [27,28].
Exposure of humans appears rare. To date only two persons are
known to have acquired their infections in the endemic region
in central North America—a 54-year-old man from Manitoba,
Canada, and a 60-year-old woman from Minnesota; however,
the potential exists for a more serious public health problem
[4].
Alveolar echinococcosis closely mimics hepatic carcinoma
and is a challenge to diagnose, even in endemic regions. CT
and MRI imaging diagnostic criteria have been described [16].
Serologic tests are usually positive at high titers [29] and highly
specific antigens [30–32] have been identified and synthesized
that, when used in serologic assays, are highly sensitive and
specific for diagnosis of AE and can distinguish this infection
from CE (E. granulosus) and other forms of echinococcosis.
Antibodies of the IgG1 and IgG4 isotypes are the most
sensitive IgG responses in alveolar echinococcosis and
monitoring of these isotypes tended to correlate with active
vs. inactive disease and successful treatment [33].
In seronegative patients PCR reactions for detection of
echinococcal-specific RNA or DNA, in closed or open biopsy
specimens, have been developed and may confirm the
diagnosis [34,35].
Clinicians familiar with this disease emphasize that man-
agement of alveolar echinococcosis, characterized by a
malignant-like proliferating cestode, is extremely difficult and
usually requires radical surgery, ideally at an early stage, and
long-term to life-long chemotherapy with benzimidazoles [36].
Choosing from the variety of treatment options requires
specific clinical experience, therefore, patients should be
referred to recognized national or regional alveolar echinococ-
cosis treatment centers [37]. Experience in AE screening
programs in Japan and elsewhere have shown that early
diagnosis reduces morbidity and mortality.
Active intervention for control of E. multilocularis presents
special difficulties because the primary cycle is almost always
sylvatic. In most regions where E. multilocularis is enzootic,
controlling the cestode by eliminating its sylvatic hosts would
be impractical for economic and logistic reasons or unaccept-
able for ecological reasons. Where exposure of humans is
mainly related to cycles involving synanthropic hosts, that is,
dogs, protection might be achieved by regular taeniacidal
treatments of dogs. Periodic mass echinococcidal treatments of
dogs as an approach to reducing the risk of human infection
was evaluated in a 10-year field trial in a village on St.
Lawrence Island, Alaska, where E. multilocularis was hyper-
endemic [38]. All dogs in this village were given praziquantel 5
mg/kg body weight at monthly intervals. This was effective in
reducing egg contamination as evidenced by an average 83%
reduction in infection prevalence in voles during the course of
the trial; prevalence in locally captured voles declined from an
average of 29% at the beginning of the trial to less than 5% at
the end. This control method, which is relatively costly, may be
applicable to other regions where synanthropic cycles create a
high risk for local human populations; such areas may include
recently described endemic foci in Gansu, Qinghai and Sichuan
provinces, China, where recent surveys showed high rates of
infection in domestic dogs [5–7,22]. The costs and benefits of
this approach require further evaluation.
3. Cysticercosis/taeniasis (T. solium)
Cysticercosis/taeniasis, caused by the ‘‘pork tapeworm’’, T.
solium, has emerged just as dramatically as echinococcosis.
Although commonly recognized by pathologists and neuro-
surgeons staffing clinics in endemic regions, international
emergence of this zoonotic infection required the development
of imaging technology [computerized tomographic (CT) and
magnetic resonance (MRI) imaging] which permitted the
demonstration of viable cysticerci in the brains of infected
persons [39]. Prior to the availability of modern diagnostic
imaging technology, antemortem diagnosis of cerebral cysti-
cercosis was mostly limited to patients with calcified cysts that
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could be demonstrated in patient’s brains by radiographic
imaging and, in deceased patients, at autopsy. Today CT and
MRI are widely available in hospital settings and the criteria
for diagnosis and staging of cysticercosis are described [39,40].
The art and science of immunologic diagnosis of cysticercosis
and taeniasis has proceeded rapidly from demonstration of the
diagnostically important antigens in larval and adult-stage
parasite stages [41,42], assessment of sensitivity and specific-
ity, isolation of the key antigenic components and development
of practical diagnostic technology for laboratory and field
applications [29,43–46]. Complementing immunologic assays
has been development of genetic markers and modification for
molecular assays [29,47] These efforts have resulted in a
variety of immunologic and molecular diagnostic techniques
that can be applied to diagnosis of cysticercosis and taeniasis
for clinical and epidemiologic studies.
Deficiencies in diagnostic detection of adult-stage intestinal
tapeworm carriers have for long limited epidemiologic studies
and control strategies based on detection and treatment of
tapeworm carriers. Detection of eggs in feces is insensitive and
nonspecific. The development of fecal antigen assays and
antibody assays for detection of antibody specific to adult-stage
infection provided technology of potential application in
epidemiologic surveys and control interventions [29,45–47].
A major factor in improving clinical management of this
disease was the development of effective chemotherapy. The
efficacy of and strategies for use of praziquantel and
albendazole have now been well-described and consensus
treatment guidelines have been developed [48–50].
Data obtained from epidemiologic surveys and clinical
experiences document that T. solium cysticercosis affects
millions of people throughout the world and is a major public
health problem for most of the developing world [39]. A recent
estimate of the prevalence of neurocysticercosis in Latin
America indicated that ¨400,000 persons have symptomatic
disease and many more are infected but not yet symptomatic
[51].
Although T. solium is not transmitted in its swine–human
life cycle in the United States, it has dramatically emerged as a
common cause of seizures among immigrants from Mexico and
other endemic areas [39,40]. Diagnoses of neurocysticercosis
(NCC) in the United States have followed the movements of
migrants in the United States from California north to Oregon
and Washington states and west to Texas, the Southeastern and
Middle Atlantic states. Although the overwhelming majority of
cases of NCC patients have been diagnosed in immigrants who
were presumably infected in their countries of origin, foci of
autochthonous transmission have been recognized from immi-
grant Taenia carriers to family members and other contacts
[39,52]. Similar situations resulting in intrahousehold transmis-
sion associated with employment of infected household
employees have been documented in Kuwait [53] and Peru [54].
Estimating the global economic impact of cysticercosis is
handicapped by inadequate information on the prevalence and
public health importance of the disease in most countries.
However, the economic losses appear to be highly significant.
In Mexico, for example, porcine cysticercosis is responsible for
a loss of more than one-half of the national investment in swine
production and for more than US$17 million annually in
hospitalization and treatment costs for humans with neurocys-
ticercosis [55]. For all of Latin America, porcine cysticercosis
accounts for an estimated economic loss of US$164 million. T.
solium taeniasis/cysticercosis is an important example of an
imported infection disease which impacts on the health of the
United States’ population but requires international coordinated
efforts to prevent or limit transmission.
In 1993, the International Task Force For Disease Eradica-
tion declared T. solium a potentially eradicable infection [56].
The parasite has several characteristics that appear to make it
vulnerable to eradication: 1) the life cycle requires humans as
definitive hosts, 2) tapeworm infections in humans are the only
source of infection for pigs, the natural intermediate hosts, 3)
the life span of pigs rarely exceeds 1 year and swineherds can
be managed, 4) no reservoirs for infection exist in wildlife, 5)
T. solium gradually disappeared from most European countries
even without control measures targeted specifically at it.
Factors credited with the elimination of T. solium include
improvements in general sanitation and economic status, the
introduction of indoor pig husbandry, and rigorous meat
inspection. Despite this historical experience and despite the
remarkable recent improvements in technology to diagnose and
treat this disease, under the conditions that exist currently in
countries where T. solium infection is endemic, and given
available resources, we do not yet know what is required to
reduce and ultimately eliminate transmission.
Although a number of intervention trials based on health
education and improved sanitation have demonstrated that
transmission of T. solium can be inhibited temporarily [45], it
has become clear that poverty and ignorance combine to thwart
changes in behavior and environment sufficient to permanently
limit or prevent transmission. Effective elimination of T. solium
will require sustained pressure on the parasite in both human
and swine hosts. A regional program in a highly endemic area
of Peru has been initiated to evaluate several intervention
strategies: mass or selected taeniacidal treatment of humans;
cysticercidal treatment of pigs; and vaccination of pigs and/or
humans. The outcome of this experience will inform future
intervention programs directed against T. solium cysticercosis.
4. Importance of international collaboration
The remarkable progress in development of technology to
diagnose, treat and prevent transmission of echinococcosis and
cysticercosis has been greatly facilitated by international
collaborations that have promoted sharing of ideas and
resources. A network of collaborating groups working on
echinococcosis was created through the auspices of the World
Health Organization (Informal Working Group on Echinococ-
cosis) and has facilitated the production of guidelines on
treatment and control [2]. Informal networks of scientists
working on cysticercosis such as the Cysticercosis Working
Group in Peru and the Cysticercosis Working Group in Asia
[57] are leading the way in progress toward improved
diagnosis, treatment and elimination of cysticercosis.
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